Patents Examined by Vanessa L. Ford
  • Patent number: 11000521
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: May 11, 2021
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Patent number: 11000588
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 11, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10961303
    Abstract: The present invention relates to a VHH which binds to a growth factor or is an antagonist for a growth factor, or binds to an implant.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 30, 2021
    Assignee: UNIVERSITEIT TWENTE
    Inventors: Hermanus Bernardus Johannes Karperien, Cornelis Theodorus Verrips, Mohamed El Khattabi, Emilie Dooms Rodrigues, Jan De Boer, Clemens Antoni Van Blitterswijk, Renee De Bruin
  • Patent number: 10947309
    Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: March 16, 2021
    Assignee: SESEN BIO, INC.
    Inventors: Michael March Schmidt, Alison Tisdale, Eric Steven Furfine, Grigorios Zarbis-Papastoitsis
  • Patent number: 10934358
    Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: March 2, 2021
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Nelson Ruiz-Opazo, Victoria L. M. Herrera
  • Patent number: 10928403
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: February 23, 2021
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 10928402
    Abstract: The present disclosure relates to biomarkers of preterm birth, biomarkers of term birth, and methods of use thereof. In particular, the present disclosure provides methods of determining whether a pregnant woman is at an increased risk for premature delivery. The present disclosure further provides methods for decreasing a pregnant woman's risk for premature delivery.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: February 23, 2021
    Assignee: NX PRENATAL INC.
    Inventors: Alan M. Ezrin, Brian D. Brohman
  • Patent number: 10913802
    Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 9, 2021
    Assignee: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Patent number: 10894828
    Abstract: The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 19, 2021
    Assignee: Universität Zürich
    Inventors: Onur Boyman, Natalia Arenas-Ramirez, Chao Zou
  • Patent number: 10881741
    Abstract: The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: January 5, 2021
    Assignee: Alkermes, Inc.
    Inventors: Juan Alvarez, Demetri T. Moustakas, Heather R. Brodkin, Leslie A. McSweeney
  • Patent number: 10869887
    Abstract: Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: December 22, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Jonathan Sockolosky, Lora Picton
  • Patent number: 10866239
    Abstract: The present disclosure provides methods of using certain biomarker expression profiles in the detection, diagnosis, prognosis, or development of treatment regimens for various cellular hyperproliferative disorders of the bowel. For example, pre-diagnostic methods comprise detecting whether the concentration of at least BAG4 in a test biological sample from a subject is elevated as compared to a control.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: December 15, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Paul Lampe, Junghyun Rho
  • Patent number: 10849966
    Abstract: Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 1, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Nelson Ruiz-Opazo, Victoria L. M. Herrera
  • Patent number: 10830773
    Abstract: The present invention relates to methods for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Insulin-like growth factor-binding protein 7 and Metalloproteinase inhibitor 2 as diagnostic and prognostic biomarkers in renal injuries.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: November 10, 2020
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 10823733
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: November 3, 2020
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura
  • Patent number: 10822400
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 3, 2020
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jocelyn Laporte, Belinda Cowling
  • Patent number: 10823742
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C-C motif chemokine 1, C-C motif chemokine 17, C-C motif chemokine 21, C-C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: November 3, 2020
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 10799589
    Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: October 13, 2020
    Assignee: BUZZARD PHARMACEUTICALS AB
    Inventors: Gregory Zarbis-Papastoitsis, Patricia Lowden, Byeong Chang
  • Patent number: 10787512
    Abstract: The invention provides monoclonal antibodies and fragments thereof that specifically bind to melatonin. Also provided are heavy chain variable region (VH) and light chain variable region (VL) sequences of such monoclonal antibodies and fragments thereof. Further provided are melatonin conjugates, and methods and uses, for example, determining, detecting, measuring, screening for, analyzing and monitoring an amount of melatonin in a sample.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 29, 2020
    Assignee: SALIMETRICS, LLC
    Inventors: Jon Eric Peterson, Daming Li, Xiuwen Liu, Meng-Yun Sandy Chou, Howard Paul Sard
  • Patent number: 10780147
    Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: September 22, 2020
    Assignees: The Regents of the University of California, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar